- Home
- PETZ vs BIAF Comparison
PETZ vs BIAF Comparison
Compare PETZ & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- BIAF
- Stock Information
- Founded
- PETZ 2002
- BIAF 2014
- Country
- PETZ China
- BIAF United States
- Employees
- PETZ N/A
- BIAF N/A
- Industry
- PETZ Steel/Iron Ore
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PETZ Industrials
- BIAF Health Care
- Exchange
- PETZ Nasdaq
- BIAF Nasdaq
- Market Cap
- PETZ 9.3M
- BIAF 7.6M
- IPO Year
- PETZ 2017
- BIAF 2022
- Fundamental
- Price
- PETZ $1.09
- BIAF $2.48
- Analyst Decision
- PETZ
- BIAF Hold
- Analyst Count
- PETZ 0
- BIAF 1
- Target Price
- PETZ N/A
- BIAF N/A
- AVG Volume (30 Days)
- PETZ 246.3K
- BIAF 5.8M
- Earning Date
- PETZ 04-28-2025
- BIAF 11-13-2025
- Dividend Yield
- PETZ N/A
- BIAF N/A
- EPS Growth
- PETZ N/A
- BIAF N/A
- EPS
- PETZ 0.26
- BIAF N/A
- Revenue
- PETZ $563,726.00
- BIAF $7,681,059.00
- Revenue This Year
- PETZ N/A
- BIAF N/A
- Revenue Next Year
- PETZ N/A
- BIAF $20.04
- P/E Ratio
- PETZ $5.51
- BIAF N/A
- Revenue Growth
- PETZ 74664.72
- BIAF 4.99
- 52 Week Low
- PETZ $0.65
- BIAF $2.34
- 52 Week High
- PETZ $1.74
- BIAF $67.12
- Technical
- Relative Strength Index (RSI)
- PETZ 49.23
- BIAF 47.39
- Support Level
- PETZ $1.06
- BIAF $2.36
- Resistance Level
- PETZ $1.19
- BIAF $7.29
- Average True Range (ATR)
- PETZ 0.06
- BIAF 0.71
- MACD
- PETZ -0.00
- BIAF -0.38
- Stochastic Oscillator
- PETZ 23.33
- BIAF 1.62
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.